About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Drug Class Review
A Comparative Overview
Nine antiretroviral agents in the protease inhibitor class are discussed with an emphasis on their safety and efficacy.
Peter J. Hughes, PharmD; Erika Cretton-Scott, PhD; Ami Teague, PharmD, BCPS, AAHIVE; and Terri M. Wensel, PharmD, BCPS
Drug Class Review
The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection
The NNRTI class of medications has contributed significantly to the management of human immunodeficiency virus-1 (HIV-1) infection. Efavirenz (Sustiva), nevirapine (Viramune), etravirine (Intelence), and the newest FDA-approved agent, rilpivirine (Edurant), all have potential benefits when used in appropriate patients.
Jason J. Schafer, PharmD, BCPS, AAHIVE; Saranyu Ravi, PharmD Candidate; Evelyn V. Rowland, PharmD Candidate; Germin Shenoda, PharmD Candidate; and Nicholas Leon, PharmD, BCPS
Sessions cover studies of clopidogrel use in colonoscopy, rifaximin in preventing spontaneous bacterial peritonitis, the effects of teduglutide use in short-bowel syndrome and parenteral nutrition, and the link between Clostridium difficile infection and antibiotics.
Abiraterone (Zytiga) for advanced prostate cancer, linagliptin (Tradjenta) for glycemic control, and peginterferon alfa-2b (Sylatron) for melanoma
Marvin M. Goldenberg, PhD, RPh, MS
The Managed Care Perspective
In an effort to control the cost of treating patients with multiple sclerosis, many health plans have introduced restraints such as requiring prior authorization, restricting the use of the drugs to FDA-approved indications, limiting the quantity of drugs that may be prescribed, and setting dosage limits.
Mari Edlin and Peter Sonnenreich, MA
Applying the Lessons Learned Can Save Lives
With fluorouracil, hours can seem like days.
Matthew Grissinger, RPh, FASCP
Medicare Part D: a chain of changes for long-term-care pharmacies and nursing homes
FDA approvals, drug indications, and updates
A Selective Progesterone Receptor Modulator For Emergency Contraception
Ulipristal acetate (ella) for emergency contraception
Andrea Kim, PharmD Candidate; and Mary Barna Bridgeman, PharmD, BCPS